Researchers at Helmholtz Munich have built a new kind of medicine to fight obesity and type‑2 diabetes. The drug works like a tiny delivery truck. First it attaches to the same receptors that natural hormones (GLP‑1 and GIP) use. Those receptors open a door into the cell.
Inside the cell, a second component called lanifibranor is released. This part turns on special switches called PPARs that control how the cell handles fat and sugar. By sending the extra drug only where the receptors are, the team hopes to avoid side effects that happen when a drug spreads through the whole body.
In mouse experiments, the hybrid drug made the animals eat less, lose weight, and keep blood sugar steadier than the standard treatments. The mice also showed better insulin action – their bodies moved sugar from the blood into tissues more efficiently, and the liver produced less sugar.
The design is often described as a “Trojan horse.” The hormone‑like part opens the gate, and the hidden drug works only after it gets inside. Because the second drug travels with the first, only a tiny dose is needed, which may reduce unwanted effects.
Besides weight loss, the study hinted at extra benefits for heart and liver health. However, these results are still from early animal testing. Human trials are needed because the GIP receptor works a bit differently in people.
The scientists say the next steps are to fine‑tune the molecule for humans and to work with industry partners to bring it to the clinic.